Molecular basis of Bcl-X L-p53 interaction: Insights from molecular dynamics simulations

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Bharatham, Nagakumar ^a   Chi, Seung Wook ^b   Yoon, Ho Sup ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; PROTEIN BAD; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL X; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DECOMPOSITION; HYDROPHOBICITY; MOLECULAR DYNAMICS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RESIDUE ANALYSIS; SEQUENCE ANALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; BCL-X PROTEIN; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054781632     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026014     Document Type: Article

References (67)

1. Thompson CB, (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462.
2. Reed JC, (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6.
3. Adams JM, Cory S, (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26: 61-66.
4. Spierings D, McStay G, Saleh M, Bender C, Chipuk J, (2005) Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis. Science 310: 66-67.
5. Skommer J, Wlodkowic D, Deptala A, (2007) Larger than life: Mitochondria and the Bcl-2 family. Leuk Res 31: 277-286.
6. Cory S, Huang DC, Adams JM, (2003) The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-8607.
7. Adams JM, Cory S, (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326.
8. Minn AJ, Swain RE, Ma A, Thompson CB, (1998) Recent progress on the regulation of apoptosis by Bcl-2 family members. Adv Immunol 70: 245-279.
9. Reed JC, (2000) Mechanisms of apoptosis. Am J Pathol 157: 1415-1430.
10. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, (2007) Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A 104: 6217-6222.
11. Petros AM, Olejniczak ET, Fesik SW, (2004) Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644: 83-94.
12. Liu X, Dai S, Zhu Y, Marrack P, Kappler JW, (2003) The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity 19: 341-352.
13. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, (2001) BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705-711.
14. Willis SN, Adams JM, (2005) Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17: 617-625.
15. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB, (2001) BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 15: 1481-1486.
16. Lane DP, (1992) Cancer. p53, guardian of the genome. Nature 358: 15-16.
17. Vousden KH, Lu X, (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
18. Hollstein M, Sidransky D, Vogelstein B, Harris CC, (1991) p53 mutations in human cancers. Science 253: 49-53.
19. Harris CC, (1996) p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 17: 1187-1198.
20. el-Deiry WS, (1998) Regulation of p53 downstream genes. Semin Cancer Biol 8: 345-357.
21. Wahl GM, (2006) Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo. Cell Death Differ 13: 973-983.
22. Haupt Y, Maya R, Kazaz A, Oren M, (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
23. Shimizu H, Burch LR, Smith AJ, Dornan D, Wallace M, (2002) The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem 277: 28446-28458.
24. Naski N, Gajjar M, Bourougaa K, Malbert-Colas L, Fahraeus R, (2009) The p53 mRNA-Mdm2 interaction. Cell Cycle 8: 31-34.
25. Vogelstein B, Lane D, Levine AJ, (2000) Surfing the p53 network. Nature 408: 307-310.
26. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M, (1995) Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 9: 2170-2183.
27. Kokontis JM, Wagner AJ, O'Leary M, Liao S, Hay N, (2001) A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function. Oncogene 20: 659-668.
28. Marchenko ND, Zaika A, Moll UM, (2000) Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 275: 16202-16212.
29. Talos F, Petrenko O, Mena P, Moll UM, (2005) Mitochondrially targeted p53 has tumor suppressor activities in vivo. Cancer Res 65: 9971-9981.
30. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303: 1010-1014.
31. Leu JI, Dumont P, Hafey M, Murphy ME, George DL, (2004) Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6: 443-450.
32. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, (2003) p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11: 577-590.
33. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR, (2005) PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309: 1732-1735.
34. Jiang P, Du W, Heese K, Wu M, (2006) The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Mol Cell Biol 26: 9071-9082.
35. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, (1997) Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275: 983-986.
36. Petros AM, Nettesheim DG, Wang Y, Olejniczak ET, Meadows RP, (2000) Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 9: 2528-2534.
37. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
38. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
39. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
40. Popowicz GM, Czarna A, Wolf S, Wang K, Wang W, (2010) Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 9: 1104-1111.
41. Phan J, Li Z, Kasprzak A, Li B, Sebti S, (2010) Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J Biol Chem 285: 2174-2183.
42. Pazgier M, Liu M, Zou G, Yuan W, Li C, (2009) Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A 106: 4665-4670.
43. Li C, Pazgier M, Yuan W, Liu M, Wei G, (2010) Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. J Mol Biol 398: 200-213.
44. Moroy G, Martin E, Dejaegere A, Stote RH, (2009) Molecular basis for Bcl-2 homology 3 domain recognition in the Bcl-2 protein family: identification of conserved hot spot interactions. J Biol Chem 284: 17499-17511.
45. Zhong H, Carlson HA, (2005) Computational studies and peptidomimetic design for the human p53-MDM2 complex. Proteins 58: 222-234.
46. Lee HJ, Srinivasan D, Coomber D, Lane DP, Verma CS, (2007) Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study. Cell Cycle 6: 2604-2611.
47. Dastidar SG, Lane DP, Verma CS, (2008) Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc 130: 13514-13515.
48. Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma C, (2010) Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies. Cell Cycle 9.
49. Xu H, Tai J, Ye H, Kang CB, Yoon HS, (2006) The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the antiapoptotic protein Bcl-Xl. Biochem Biophys Res Commun 341: 938-944.
50. Xu H, Ye H, Osman NE, Sadler K, Won EY, et al. (2009) The MDM2-binding region in the transactivation domain of p53 also acts as a Bcl-X(L)-binding motif. Biochemistry 48: 12159-12168.
51. Berendsen HJC, van der Spoel D, van Drunen R, (1995) GROMACS: a message-passing parallel molecular dynamics implementation. CompPhys Commun 91: 43-56.
52. van der Spoel D, Lindahl E, Hess B, van Buuren AR, Apol E, (2005) (2005) Gromacs User Manual version 4, Available:www.gromacs.org.
53. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, (2004) AMBER9. an Francisco: University of California.
54. Tsui V, Case DA, (2000) Molecular dynamics simulations of nucleic acids with a Generalized Born solvation model. J Am Chem Soc 122: 2489-2498.
55. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33: 889-897.
56. Case DA, (1994) Normal-mode analysis of protein dynamics. Curr Opin Struct Biol 4: 285-290.
57. Connolly ML, (1983) Solvent-accessible surfaces of proteins and nucleic acids. Science 221: 709-713.
58. Thompson JD, Higgins DG, Gibson TJ, (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
59. Zondlo SC, Lee AE, Zondlo NJ, (2006) Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53. Biochemistry 45: 11945-11957.
60. Schon O, Friedler A, Bycroft M, Freund SM, Fersht AR, (2002) Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 323: 491-501.
61. Bottger A, Bottger V, Garcia-Echeverria C, Chene P, Hochkeppel HK, (1997) Molecular characterization of the hdm2-p53 interaction. J Mol Biol 269: 744-756.
62. Lee H, Mok KH, Muhandiram R, Park KH, Suk JE, (2000) Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J Biol Chem 275: 29426-29432.
63. Lama D, Sankararamakrishnan R, (2008) Antiapoptotic Bcl-XL protein in complex with BH3 peptides of proapoptotic Bak, Bad, and Bim proteins: comparative molecular dynamics simulations. Proteins 73: 492-514.
64. Humphrey W, Dalke A, Schulten K, (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38, 27-38.
65. Kutzki O, Park HS, Ernst JT, Orner BP, Yin H, (2002) Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J Am Chem Soc 124: 11838-11839.
66. Yin H, Lee GI, Sedey KA, Kutzki O, Park HS, (2005) Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. J Am Chem Soc 127: 10191-10196.
67. Ha JH, Won EY, Shin JS, Jang M, Ryu KS, (2011) Molecular mimicry-based repositioning of nutlin-3 to antiapoptotic Bcl-2 family proteins. J Am Chem Soc 133: 1244-1247.